Investor Presentaiton
Nurtec ODT - one of the strongest recent launches in biopharma
March 2018
Positive pivotal Nurtec ODT
efficacy studies(1)
December 2018
February 2020
March 2020
Positive Nurtec ODT long-
term safety study (2)
FDA approval of Nurtec ODT
for acute migraine (3)
Positive Phase 3 Nurtec ODT
migraine prevention study (4)
May 2021
FDA approval of Nurtec ODT
for migraine prevention (5)
November 2021
May 2022
Biohaven Ex-U.S.
collaboration with Pfizer (6)
Pfizer to acquire Biohaven (7)
Encouraging oral CGRP (8) volumes
Total prescriptions (TRX)(9)
Successful Nurtec ODT launch in US(10)
Nurtec ODT global net revenue ($ in millions)
Pfizer expects significant peak sales(7)
80,000
April 2020
64
463
1,668
1,302
912
2,177
Present
2020
2021
2022e 2023e 2024e 2025e
CGRP: calcitonin gene-related peptide
>$6bn
1. Biohaven press release, March 26, 2018. 2. Biohaven press release, December 10, 2018. 3. Biohaven press release, February 27, 2020. 4. Biohaven press release, March 30, 2020. 5. Biohaven press release, May
10. Visible Alpha consensus as of May 2022.
ROYALTY PHARMA 27, 2021. 6. Biohaven press release, November 9, 2021. 7. Pfizer press release and presentation, May 10, 2022. 8. Oral CGRPs include Ubrelvy, Quilipta and Nurtec ODT. 9. IQVIA SMART: TRX volume to April 2022.
72View entire presentation